Coagulation Markers Market Report 2024

The coagulation markers market size has grown strongly in recent years. It will grow from $1.09 billion in 2023 to $1.16 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historical period can be attributed to several factors including the rising prevalence of cardiovascular diseases, an aging population, increasing rates of surgical procedures, improved awareness and early diagnosis, government initiatives and funding in healthcare, and the expansion of healthcare infrastructure.

The coagulation markers market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to several factors including the increasing incidence of chronic diseases, greater adoption of personalized medicine approaches, a growing global population, rising healthcare expenditures, and expansion into emerging markets. Major trends expected during this period include the integration of AI and machine learning in diagnostics, advancements in the development of novel biomarkers, improved point-of-care technologies, automation in laboratory settings, the proliferation of wearable health technologies, the expansion of telehealth and remote monitoring capabilities, and the adoption of sustainable diagnostic practices.

The coagulation markers market is expected to grow significantly due to the increasing prevalence of blood disorders. These disorders encompass various conditions that impact the blood's ability to function properly, and their prevalence is rising due to factors such as aging populations, improved awareness, and enhanced diagnostic capabilities. Coagulation markers play a crucial role in diagnosing and managing these disorders by evaluating clotting function, detecting abnormalities, and monitoring treatment effectiveness for conditions such as hemophilia and thrombosis. For example, the Leukaemia Foundation reported in May 2024 that the number of Australians living with blood cancers or disorders is projected to surpass 275,000 by 2035, highlighting the escalating demand for coagulation markers.

Leading companies in the coagulation markers market are concentrating on technological advancements to enhance diagnostic precision, operational efficiency, and speed of results, thereby improving patient care. Automated blood coagulation analyzers represent one such innovation, automating various tests to assess blood clotting function swiftly and accurately. For instance, Sysmex Corporation, a Japanese leader in in-vitro diagnostic solutions, introduced the CN-6000 and CS-5100 automated blood coagulation analyzers in July 2021. The CN-6000 offers a throughput of up to 240 tests per hour with features such as automatic sample pre-treatment and quality control management. Meanwhile, the CS-5100 is a compact analyzer suitable for smaller laboratories, capable of handling up to 120 tests per hour. Both analyzers support a wide range of coagulation assays, streamline testing workflows, and enhance patient care by reducing turnaround times.

In September 2021, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a Chinese provider of medical devices and solutions, acquired HyTest Ltd. to strengthen its research and development capabilities in in-vitro diagnostics. This strategic move aims to sustain HyTest's leadership in IVD raw materials, particularly in antibody and antigen design, thereby enhancing Mindray's competitiveness and growth prospects in the coagulation markers segment. HyTest Ltd., based in Finland, specializes in providing antigen and antibody reagents, including those for blood coagulation markers.

Major companies operating in the coagulation markers market are Siemens Healthineers, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Werfen Group, Nihon Kohden Corporation, Randox Laboratories Ltd, Stago Group, Sekisui Diagnostics, Helena Laboratories Italia Spa, Tulip Diagnostics Ltd, Trinity Biotech PLC, CTK Biotech Inc., International Technidyne Corporation (ITC), Diazyme Laboratories Inc., AdvaCare Pharma USA (AccuQuik Test Kits), Technoclone GmbH, BioMedica Diagnostics Inc., Eurolyser Diagnostica GmbH, Goldsite Diagnostics Inc., Hipro Biotechnology Co. Ltd., HYPHEN BioMed.

North America was the largest region in the coagulation markers market in 2023. The regions covered in the coagulation markers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the coagulation markers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Coagulation markers are substances in the blood that provide insight into the coagulation or clotting processes. These markers play a crucial role in diagnosing and monitoring various coagulation disorders, assessing the risk of bleeding or thrombosis, and guiding appropriate treatment strategies.

The main products used as coagulation markers include the D-dimer assay and the fibrinogen assay. The D-dimer assay is a blood test that measures the presence of D-dimer, a protein fragment formed when a blood clot breaks down. This test can utilize different sample types such as plasma or whole blood, employing technologies such as fluorescence immunoassay, enzyme-linked immunosorbent assay (ELISA), rapid tests, and particle-enhanced immunoturbidimetric assay. It is applied in conditions such as deep venous thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), trauma, and others. End users of these assays include hospitals, specialty clinics, academic and research institutes, and diagnostic laboratories.

The coagulation markers market research report is one of a series of new reports that provides coagulation markers market statistics, including coagulation markers industry global market size, regional shares, competitors with a coagulation markers market share, detailed coagulation markers market segments, market trends and opportunities, and any further data you may need to thrive in the coagulation markers industry. This coagulation markers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The coagulation markers market consists of revenues earned by entities providing services such as manufacturing and distribution of coagulation marker testing kits, diagnostic services, research and development of new coagulation markers, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The coagulation markers market also includes sales of coagulation testing kits, point-of-care testing devices, and software solutions for data management and analysis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.